Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis). Founded in 2009, headquartered in Seattle, United States. RareCyte operates in the Genomics, Life Sciences Platforms and Tools, Clinical Genomics sectors. The company focuses on Detection and Quantification, NGS Reagents. The company has raised $114.3M in Series C funding. Notable investors include Health Quest Capital, 5AM Ventures, Telegraph Hill Partners, F-Prime Capital, Arboretum Ventures, Agilent, among others.
RareCyte
Series CDeveloper of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging…
About
Business model
Genomics > Enabling Technologies > Kits and Reagents > Detection and Quantification,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > NGS Reagents
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.